Diabetes Mellitus Clinical Trial
Official title:
Comparison of Vehicle Delivery Depth Using the NovoFine® 5 mm Needle With or Without a Skin Fold and Inserted at Either 45 or 90 Degrees
Children and adolescents with type 1 diabetes mellitus are required to inject insulin daily.
The injection technique should reliably deposit insulin into subcutaneous fat while
minimizing inadvertent delivery into either the skin or the underlying muscle, both of which
are associated with suboptimal outcomes. The use of shorter, thinner needles reduces the
incidence of intramuscular delivery and is associated with reduced discomfort, but increases
the risks of both shallow (intradermal) delivery and of loss of insulin through backflow to
the skin surface.
In the current study, 240 subjects (children and adults) will receive multiple injections of
small volumes of sterile air in the thigh and abdomen using 5 mm Novofine® needles, to
simulate insulin injections performed at the two sites using various injection techniques
(perpendicular or angled needle, with or without skin fold). Ultrasound visualisation of the
injected air will allow determination of the incidence of intradermal or intramuscular
delivery using the various delivery methods in the trial. In addition, adult subjects will
receive injections of a liquid test medium in order to determine the incidence and extent of
backflow. Qualitative data on perceived discomfort and information on body composition will
also be collected. This investigation will form the basis for recommendations regarding
preferred injection technique where 5 mm needles are used.
Rationale:
The injection techniques used with children and adolescents with type 1 diabetes mellitus
should reliably deposit insulin into subcutaneous fat while minimizing inadvertent
intramuscular (IM) insulin injections. Surprisingly, injection technique varies among
centres, tends to be protocol driven and is usually dependent on needle length. The
recommended injection procedure for diabetic children in our centre include a lifted or
pinched skin fold either on the abdomen, thigh or buttocks with perpendicular injection of 8
mm syringes and angled injection of 12.7 mm syringes. However both 8 and 12.7 mm needles,
have been associated with frequent IM injections with rates of 38% and 86% respectively,
reported using a perpendicular insertion (1, 2). IM injection of regular, NPH and glargine
insulin has been associated with more rapid insulin release, variability in glycaemic
control and an increased risk of hypoglycaemia (3-5).
The risk of IM insulin deposition is known to be related to a number of variables including
younger age, male sex, lower body mass index (BMI), injection technique (angle of insertion
and a lifted or pinched skinfold), and needle length (1, 2, 6-8). Reducing the length of the
insulin needle reduces the incidence of IM injections, however the use of 5 mm insulin
needles may result in insulin being administered too superficially in the dermal layer (9,
10). The consequence of intradermal insulin deposition is largely unknown, but may lead to
increased insulin leakage, increased injection pain, and an increased immune response (10).
Little information is known about skin thickness, although it does vary with age, obesity
and puberty (personal observations).
Smaller, thinner needles are also associated with reduced pain and discomfort. However they
may cause greater insulin loss after the injection. This latter issue may also reflect the
injection technique used with anecdotal evidence suggesting angled techniques may reduce
insulin loss.
Objectives:
Primary Objective: To locate and compare simulated insulin injections in children,
adolescents and adults with diabetes given with 5 mm needle using a 45 degree and 90 degree
injection angle, with and without skin fold in order to provide injection guidelines.
Secondary Objectives:
1. To study the thickness of dermis in abdomen and thigh in children, adolescents and
adults with normal weight and over weight/obese.
2. To evaluate the distance from skin surface to muscle fascia (abdomen/thigh) with and
without compression of the skin in children, adolescents and adults with normal weight
and over weight/obese.
3. To quantify the amount of backflow of the test medium to the skin surface in adults and
investigate whether there is a substantial clinically relevant difference among various
techniques.
4. To assess comfort and ease of injection technique
This trial is a single-centre and open-label phase IV trial. The investigation will be
performed in three visits. Patients screening will be done at the first visit, 2 ± 1 days
prior to the second visit day. The second and the third visit will be performed with two
weeks ± 3 days apart. At the second visit day all the subjects will receive (performed by
study nurse) injected sterile air corresponding to 20 IU of insulin (200 µl) with Novofine 5
mm needles perpendicularly in abdomen and thigh with and without skin fold, giving in total
four injections at this visit. Following the injection, sterile air deposition will be
visualized by ultra sound (GELogic5 or a Phillips IU-22 machine). A 12.5 MHz linear array
transducer will be used. This measures depth up to 3cm accurately. To assess dermis and air
after injections a 1cm standoff will be employed. This is standard ultrasound technique to
examine changes close to the transducer and we developed expertise using this technique
during our previous study. Because of the better visualization using a standoff smaller,
more physiological, volumes of air can be reliably injected. Thickness of (i) dermis and
(ii) distance from skin surface to muscle fascia at the respective injection places will
also be measured by ultrasound both with and without lifted skin fold prior to injection.
The adults will be then injected with 200 µl of test medium with a 5 mm needle
perpendicularly in abdomen and thigh with a lifted skin fold, providing an additional four
injections to the adults. Possible backflow to skin surface will be absorbed by filter paper
and quantified by scale. Injection speed will be measured by time from start to end of
injection. After each injection subjects will be asked to complete a visual analog pain
scale and after the injections they will be asked their preference for needle technique and
site of injection. On the third visit day all subjects will be injected 200µl sterile air
(performed by study nurse) with 5 mm needles at 45degrees with and without pinch-up
technique in the abdomen and thigh, providing a total of four injections to each subject. In
addition, 200µl test medium with 5 mm needle at 45degrees in abdomen and thigh with and
without lifted skin fold will be injected to adults. Possible backflow to skin surface will
be absorbed by filter paper and quantified by scale. The weighing scale must be able to
measure with three decimals in the metric system (microgram). A 10 cm visual analog pain
scale will be used to assess the discomfort of the injections in comparison to standard
injections.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |